Paragon Clinical Research Inc is categorized under Medical Research in Cranston, RI and active since 2000.
Paragon Clinical Research Inc was established in 2000, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Medical Research business, which does work in the B2B market, and is classified as a Medical Research, under code number 541720 by the NAICS.
If you are seeking more information, feel free to contact Dennis Mikolich at the company’s single location by writing to 1150 Reservoir Avenue # 103, Cranston, Rhode Island RI 02920 or by phoning (401) 943-8685. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Paragon Clinical Research Inc |
| Contact Person: | Dennis Mikolich |
| Address: | 1150 Reservoir Avenue # 103, Cranston, Rhode Island 02920 |
| Phone Number: | (401) 943-8685 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2000 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Medical Research |
| SIC Code: | 8733 |
| NAICS Code: | 541720 |
| Share This Business: |
Paragon Clinical Research Inc was started in 2000 to provide professional Medical Research under the SIC code 8733 and NAICS code 541720. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Dennis Mikolich for inquiries that concern Paragon Clinical Research Inc by calling the company number (401) 943-8685, as your correspondence is most welcome. Additionally, the physical location of the single location of Paragon Clinical Research Inc can be found at the coordinates 41.769481,-71.454824 as well as the street address 1150 Reservoir Avenue # 103 in Cranston, Rhode Island 02920.
For its online presence, you may visit Paragon Clinical Research Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.